Involvement of Protein Kinase B (Akt) in Cardioprotection Carried out by Oral Administration of Stevioside

Authors

  • Victoria Mestre Cordero Physiology Unit, Pharmacy and Biochemistry School. University of Buenos Aires . IQUIMEFA-CONICET
  • Débora Vélez Physiology Unit, Pharmacy and Biochemistry School. University of Buenos Aires . IQUIMEFA-CONICET
  • Sofia Harriet, Physiology Unit, Pharmacy and Biochemistry School. University of Buenos Aires . IQUIMEFA-CONICET
  • Rodrigo Tsacalian, Physiology Unit, Pharmacy and Biochemistry School. University of Buenos Aires . IQUIMEFA-CONICET
  • Romina Hermann Physiology Unit, Pharmacy and Biochemistry School. University of Buenos Aires . IQUIMEFA-CONICET
  • Marina Prendes Physiology Unit, Pharmacy and Biochemistry School. University of Buenos Aires . IQUIMEFA-CONICET
  • María Gabriela Physiology Unit, Pharmacy and Biochemistry School. University of Buenos Aires . IQUIMEFA-CONICET

Keywords:

Wistar rats, electron microscopy, cardioprotection, protein kinase B, stevioside

Abstract

Introduction: Stevia rebaudiana bertoni is an herbaceous plant widely distributed and used in Paraguay and Brazil, known for its sweetener character. Stevioside (E), a diterpenoid glycoside, is the main non-caloric sweetener extracted from Stevia leaves. Several papers have been published about stevia and its properties as antihypertensive, insulinotropic, antihyperglycemic and antitumor.  However, there are few documented findings on cardiovascular effects mediated by stevioside. In previous studies carried out in our laboratory, we demonstrated that oral administration of E improved the recovery of contractile activity in hearts subjected to I-R and decreased the infarct size. These effects were, at least in part, reverted by the administration of Wortmannin (W), an upstream inhibitor of Akt.

Objective: The aim of the present study was to investigate the mitochondrial morphology and the rate of ATP synthesis after oral administration of E (168 mg/kg for 15 days) and its relation with the activation profile of Akt and GSK3β, in Langendorff perfused rat hearts subjected to I-R.

Material and Methods: Hearts from female Wistar rats (200-250g) fed ad libitum were used. W (100nM) was added 15 min before I. Mitochondrial ultrastructure was analyzed by electron microscopy, the measurement of mitochondrial ATP synthesis was made by the luciferin-luciferase method and the activation profile of Akt and GSK3b were studied by western blot considering Akt-P/Akt-T and GSK3b-P/GSK3b-T, respectively. ANOVA, n=8/group.

Results: At the end of reperfusion, results showed an increase in mitochondrial ATP synthesis rate of hearts treated with E that was partly canceled by the administration of W (C: 66.3±6.5, W: 59.5±6.1, E: 87.3±3.7*, E+W: 64.6±6.9 nmol/min/mg mitochondrial protein; *p<0.05 vs all groups) Likewise, electron micrographs showed better mitochondrial conservation in the group treated with E. Akt presented higher phosphorylation with E treatment (C: 1.26±0.19, W: 1.16±0.07, E: 1.80±0.16*, E+W: 0.86±0.16 AU; *p<0.05 vs all groups). Moreover, GSK3b phosphorylation was higher in the E group with respect to the control group, being partially reverted with W (C: 1.03±0.11, W: 1.04±0.15, E: 1.88±0.05*, E+W: 1.63±0.18 AU; *p<0.05 vs C and W).

Conclusions: These findings suggest that oral administration of E presents cardioprotective effects which includes greater preservation of mitochondrial function and morphology and could be partly mediated by Akt activation.

 

Keywords: Wistar rats, electron microscopy, cardioprotection, protein kinase B, stevioside

Downloads

Download data is not yet available.

Downloads

Published

2020-01-28

How to Cite

1.
Mestre Cordero V, Vélez D, Harriet, S, Tsacalian, R, Hermann R, Prendes M, et al. Involvement of Protein Kinase B (Akt) in Cardioprotection Carried out by Oral Administration of Stevioside. Rev Cubana Inv Bioméd [Internet]. 2020 Jan. 28 [cited 2025 Aug. 31];38(5). Available from: https://revibiomedica.sld.cu/index.php/ibi/article/view/487

Issue

Vol. 38 (2019): Suplemento Especial: II PanAmerican Congress of Physiological Sciences

Section

SHORT COMMUNICATIONS

License

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes: Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons (CC-BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).

Como Revista Cubana de Investigaciones Biomédicas forma parte de la red SciELO, una vez los artículos sean aceptados para entrar al proceso editorial (revisión), estos pueden ser depositados por parte de los autores, si estan de acuerdo, en SciELO preprints, siendo actualizados por los autores al concluir el proceso de revisión y las pruebas de maquetación.